Sanofi-Aventis’s New JV Will Provide Entry into China’s OTC Market

ChinaBio Today submits: Sanofi-Aventis (NYSE: SNY ) signed a letter of intent last Saturday to establish a joint venture with Minsheng Pharmaceutical Group of Hangzhou. The JV will focus on OTC vitamin and mineral products. Minsheng already produces the best selling product in the sector: 21-Super Vita multivitamin-multimineral tablets. For Sanofi-Aventis, the JV will provide an entry into China’s OTC market. Sanofi-Aventis will have the majority share in the JV. No other financial details